MIRAPEX helps reserve
the use of levodopa
Learn more
Learn more about
initial monotherapy
with MIRAPEX
Click here

FOR THE INITIAL AND LONG-TERM TREATMENT OF PARKINSON'S DISEASE (PD)

MIRAPEX offers dosing choices for ease of titration*

Mirapex titration chart
  • Effective dosage range from 1.5 mg/day to 4.5 mg/day, with or without levodopa*

*For patients with normal renal function.

MIRAPEX offers a convenient Starter Kit

  • Helpful patient materials
  • Customized titration options

MIRAPEX is extensively covered31,32

  • Reimbursed by 99% of HMOs31
  • Listed on formulary for 98% of prescription drug plans (PDPs) and Medicare (MAPD) enrollees32

MIRAPEX safely and effectively helps you meet the distinct needs of all patient types

  • MIRAPEX can be titrated slowly in small increments of 0.125 mg to 0.25 mg, providing the optimal balance of symptom improvement and tolerability
  • Dosing can be increased, as needed, while keeping levodopa dose stable
  • When used in combination with levodopa, a reduction in the levodopa dose should be considered

MIRAPEX plasma levels over 24 hours from a single dose27†

  • The half-life of MIRAPEX is 8 to 12 hours
  • Can be administered without regard to meals
Mirapex taken with food and while fasting

† The relationship between pharmacokinetics and pharmacodynamics has not been established.

 
 

Important Information about MIRAPEX: MIRAPEX is indicated for the treatment of the signs and symptoms of idiopathic Parkinson’s disease (PD).

Patients have reported falling asleep without perceived warning signs during activities of daily living, including operation of a motor vehicle, which sometimes resulted in accidents. Hallucinations and postural (orthostatic) hypotension may occur. In clinical trials for early PD, the most commonly reported side effects of MIRAPEX that were more frequent than with placebo are nausea (28% vs. 18%), dizziness (25% vs. 24%), somnolence (22% vs. 9%), insomnia (17% vs. 12%), asthenia (14% vs. 12%), and constipation (14% vs. 6%). In clinical trials for advanced PD, the most commonly reported side effects of MIRAPEX that were more frequent than with placebo are postural hypotension (53% vs. 48%), dyskinesia (47% vs. 31%), extrapyramidal syndrome (28% vs. 26%), insomnia (27% vs. 22%), dizziness (26% vs. 25%), accidental injury (17% vs. 15%), hallucinations (17% vs. 4%), and dream abnormalities (11% vs. 10%).

Patients and caregivers should be informed that impulse control disorders and compulsive behaviors have been reported in patients taking dopamine agonists, including MIRAPEX.

Please see full Prescribing Information.

This information is intended for U.S. residents only.